ACLX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Arcellx Inc (ACLX) is not a good buy for a long-term beginner investor at this time. The stock is currently trading at $115.09, which aligns with Gilead's acquisition price of $115 per share. Analysts have downgraded the stock to Neutral or Hold, and there is no expectation of competing offers. The company's financial performance shows declining revenue and negative net income, making it less attractive for long-term growth. Additionally, insider selling has increased significantly, and there are no recent positive catalysts or trading signals to suggest a strong buying opportunity.
The stock is overbought with an RSI of 86.244, and the MACD histogram is negative at -0.952, indicating a potential bearish trend. However, moving averages are bullish (SMA_5 > SMA_20 > SMA_200), and the stock is trading near its resistance level of $115.062.
NULL. No recent news or events suggest a positive catalyst for the stock. The acquisition by Gilead is already priced into the stock.
Significant insider selling (642.87% increase in the last month). Analysts have downgraded the stock to Neutral or Hold due to the acquisition, with no competing offers expected. Declining revenue and negative net income further weigh on the stock's attractiveness.
In Q4 2025, revenue dropped by 89.17% YoY to $1,654,000. Net income improved by 23.43% YoY but remains negative at -$58,112,000. EPS increased by 14.94% YoY to -1, and gross margin remained at 100%. Overall, the financials do not indicate strong growth potential.
Analysts have downgraded the stock to Neutral or Hold, with a price target of $115, aligning with Gilead's acquisition offer. No competing offers are expected, and the deal is anticipated to close in Q2 2026.
